Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Telix Pharmaceuticals Limited
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
May 22, 2026
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
May 22, 2026
Telix and Regeneron Announce Strategic Radiopharma Collaboration
May 21, 2026
Telix Strengthens Board with Additional Director Appointments
May 21, 2026
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
May 20, 2026
Telix Appoints David Gill as Non-Executive Director
May 20, 2026
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
May 18, 2026
Telix Full Year Results 2025 Investor Webcast Notification
February 3, 2026
←
Previous Page
1
2
3